New Blood Advances issue out now featuring: Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma buff.ly/cwtor5a

CCR4 mutations and Moga-associated cAEs were related to better OS. buff.ly/Fi6QexZ #hemesky

Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring buff.ly/dVepKnY #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 📚 Identifying pediatric patients with sickle cell disease at high risk of experiencing chronic pain after HSCT 📖 Read the full article here. buff.ly/AgBdW37

Racial disparities in multiple myeloma buff.ly/Z9eZ58D

ORR was 29% in heavily pretreated patients who had received prior BCMA-targeted therapy. buff.ly/zFa0r1C #hemesky

Weight loss and oral toxicities often cause treatment modifications. buff.ly/vvEyPgD #hemesky

Age-related decline of DCAF8 expression in HSCs leads to functional defects. buff.ly/fd03KvX #hemesky

Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia buff.ly/3zmKnnB #hemesky

An ethical allocation scheme for scarce gene therapies in sickle cell disease and transfusion-dependent β-thalassemia buff.ly/z0D8Azi #hemesky

A locally adapted regimen for the treatment of pediatric ALL in Cambodia resulted in a 2-year RFS of 66%. buff.ly/CoUQShj #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 🔊 Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma 🎧https://buff.ly/E9RQy1v

This genetic risk is stronger in patients with NPM1 mutations. buff.ly/WyjEJoz #hemesky

🔊 Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML 🎧 buff.ly/fgf4LTP

Through drug repositioning, we found that ambroxol induces myeloma cell death by inhibiting late-stage autophagy. buff.ly/PKS4Scr #hemesky

🔊 Review Series on Acute Lymphoblastic Leukemia (ALL) 🎧 buff.ly/Na549mu

Longitudinal follow-up with trainees was key to support the growth of BMT in LMIC and build global partnerships. buff.ly/qik5LQ8 #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 🔊 First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia 🎧 buff.ly/jmjBsdI

Meet Dr. Melody Smith, who joined Stanford University School of Medicine in 2021, where she established her independent lab. Her research focuses on cell-intrinsic and cell-extrinsic factors that impact CAR T cell efficacy and safety. Learn more about her and why she peer-reviews: buff.ly/9aizQ8Z

The age-adjusted rate of developing BIA-ALCL for women with BRCA was 16 times the rate of BIA-ALCL without BRCA. buff.ly/02ruLac

REMPs have reduced access to CART-BCMA therapies for MM. buff.ly/knK3l3y #hemesky

Moving beyond the eyeball test for fitness assessment in AML buff.ly/eXzBh2Q #hemesky

Early recognition of AL amyloidosis will improve the prognosis of these patients. buff.ly/pgX8Hgw #hemesky

New Blood issue out now featuring: Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX buff.ly/kZKWnvM

🎙️ Just published a new episode of Blood Podcast: Review Series on Acute Lymphoblastic Leukemia (ALL). Have a listen:

Multifaceted cfDNA profiling in mantle cell lymphoma buff.ly/dnIdE8v #hemesky

🎙️ Just published a new episode of Blood Podcast: Azacitidine holds promise in VEXAS syndrome; a step forward in precision blood matching; identifying a new vulnerability in TP53-mutated AML. Have a listen:

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 🔊 Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans 🎧 buff.ly/qM3itrZ

PDA scores (≥4) can recognize the onset of ICANS a median of 68 hours prior to clinical symptoms. buff.ly/BO4YPgA #hemesky

This genetic risk is stronger in patients with NPM1 mutations. buff.ly/WyjEJoz #hemesky

New Blood ICT issue out now featuring: Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia buff.ly/AewfIWH

Meet Dr. Steven Lane, a clinical hematologist in Brisbane, Australia, and head of a busy research group at the Queensland Institute of Medical Research. Learn more about him and why he serves as a peer reviewer for the Blood Journals portfolio: buff.ly/KkjOqYQ #PeerReviewWeek

“Optimizing” HLH diagnoses in patients with lymphoma buff.ly/WhIBaqA #hemesky

Identifying competencies is a critical step for implementing CBME in hematology residency programs. buff.ly/bT56C1Y #hemesky

The quadruplet regimen Dara-CTD was active and safe as frontline therapy in ASCT-eligible NDMM. buff.ly/iQBWuud #hemesky

Meet another one of our esteemed peer-reviewers for #PeerReviewWeek! Dr. Fernanda Orsi is a classical hematologist and Associate Professor in the Department of Pathology at the University of Campinas (UNICAMP), Brazil. Learn more about why she peer-reviews here: buff.ly/XhRsTXA

Reality bites: allocating gene therapy for hemoglobinopathies buff.ly/9ICNqxG #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD! 📚 Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis 🎧 Listen to the full episode here. buff.ly/LyxrSuu

New study in #Blood VTH: We show that the AcuStar HIT-IgG (Werfen) CLIA is a reliable & fast ⏱️ diagnostic tool for #HIT with strong agreement vs anti-PFA/H ELISA (Hyphen) & SRA @davidmsmadja.bsky.social @hopitalpompidou.bsky.social @bloodjournals.hematology.org ashpublications.org/bloodvth/art...

We are excited to announce our new #NDLR2026 Meet-the-Editor session, with Editors-in-Chief, Prof Andrew Roberts, @bloodjournals.hematology.org and Prof @jancools.bsky.social, @hemasphere-journal.bsky.social who will share their invaluable insights on #publishing in high-impact #hematology journals.

An expert panel of hematologists from LATAM developed recommendations to address region-specific challenges in MF care. buff.ly/x4AbIgn #hemesky

Pharmacological inhibition of PPARγ enhanced sensitivity to VEN/DEC in resistant AML, suggesting PPARγ as a potential therapeutic target. buff.ly/YMaExu3 #hemesky

Meet Dr. Hanny Al-Samkari, Peggy S. Blitz Endowed Chair in Hematology/Oncology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Learn more about him and why he serves as a peer reviewer for the Blood Journals portfolio: buff.ly/SWkoVHz #PeerReviewWeek

ELEVATE-ing clinical trial reporting in CLL buff.ly/FwUhcEw #hemesky

HCAR2 the rescue: sensing heme, steering inflammation buff.ly/pDc2stY #hemesky

Patients without hematological response experienced an unfavorable evolution of both diseases: CML and SARS-CoV-2 infection. buff.ly/pVXZmRe #hemesky

🌍 September is Sickle Cell Disease Awareness Month and together we are working to #ConquerSCD! 📚 Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis 📖 Read the full article here. buff.ly/fVR0aLN

In vivo myeloid depletion reduces leukemia burden in the CNS and enhances chemotherapy to improve mouse survival. buff.ly/9Y3tWdk #hemesky

Inflammatory memory of stem cells: implications for hematologic diseases buff.ly/QBUFcjd #hemesky

🔊 Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutations 🎧 buff.ly/61xbErO